Corcept Therapeutics Azioni (NASDAQ: CORT)

Ultime notizie per Corcept Therapeutics (NASDAQ:CORT) Azioni

Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

CORTS Trust for Bellsouth 7.00% CorTS Ctfs due 12/01/2095

CORTELCO SYS PUERTO RICO by Cortelco Systems Puerto Rico Inc.

Cortelco Systems Puerto Rico Inc

Corteva Inc

Cortex

Structures Products Cp 8% CorTS Issued by Peco Energy Cap Tr II Preferred Stock

Corts Trust Peco Energy Capital Trust III

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 20 years by 7.21% on an annualized basis producing an average annual return of 15.13%. Currently, Corcept Therapeutics has a market capitalization of $7.34 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 20 years ago, it would be worth $16,746.85 today based on a price of $69.59 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744818312_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

CORT

$1000 Invested In Corcept Therapeutics 20 Years Ago Would Be Worth This Much Today

Biotech

General

Corcept Begins Trial Of Relacorilant Plus Nab-Paclitaxel And Bevacizumab For Patients With Platinum-Resistant Ovarian Cancer

The S&amp;P400 index, which tracks the top mid-cap stocks, fell 9.1% last week and 4.8% last Friday. However, these mid-cap stocks emerged as winners. Are they in your portfolio?
<ol>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares surged 36.28% after the company disclosed that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded <a href="https://www.benzinga.com//node/44569564" target="_blank" rel="noreferrer noopener">independent central review (PFS-BICR)</a>.</li>
<li>Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) stock escalated 28.44% after the company announced Rocket Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) will acquire it in <a href="https://www.benzinga.com//node/44565671" target="_blank" rel="noreferrer noopener">a $9.4 billion all-stock deal</a>.</li>
<li>Verra Mobility Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRRM#NASDAQ">VRRM</a>) shares rose 10.90%.</li>
<li>Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) stock rose 10.35% after Deutsche Bank upgraded it from Hold to Buy <a href="https://www.benzinga.com/quote/gt/analyst-ratings" target="_blank" rel="noreferrer noopener">and announced a $13 price forecast</a>.</li>
<li>Progress Software Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) stock upped 9.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/44570749" target="_blank" rel="noreferrer noopener">first-quarter financial results</a>.</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) stock rose 9.24% after the company reported better-than-expected third-quarter financial results and issued <a href="https://www.benzinga.com//node/44629158" target="_blank" rel="noreferrer noopener">FY25 sales guidance above estimates</a>.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) stock rose 5.62%.</li>
<li>Loar Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOAR#NYSE">LOAR</a>) shares increased 5.26% after the <a href="https://www.benzinga.com//node/44560215" target="_blank" rel="noreferrer noopener">company reported quarterly results</a>.</li>
<li>PVH Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) shares gained 4.68% last week following strong <a href="https://www.benzinga.com//node/44572437" target="_blank" rel="noreferrer noopener">Q4 financial results</a> and the announcement of plans to enter into a $500 million accelerated share repurchase program.</li>
</ol>
Photo by Sorbis via Shutterstock

Mid Cap

Movers

CELH

COOP

LOAR

PRGS

VRRM

How Some Mid Cap Stocks Outshone The S&P 400's Dramatic Drop Last Week (Mar 31-Apr 4)

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Overweight and raises the price target from $128 to $131.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Corcept Therapeutics, Raises Price Target to $131

<h3>Gainers</h3>
<ul>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock moved upwards by 488.1% to $2.12 during Tuesday's regular session. The market value of their outstanding shares is at $7.0 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock increased by 236.5% to $0.87. The market value of their outstanding shares is at $13.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares moved upwards by 55.1% to $2.28. The market value of their outstanding shares is at $3.6 million. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares moved upwards by 53.55% to $72.22. The market value of their outstanding shares is at $392.6 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) shares moved upwards by 39.56% to $0.6. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock moved upwards by 37.91% to $0.32. The company's market cap stands at $1.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) shares declined by 32.3% to $0.65 during Tuesday's regular session. The market value of their outstanding shares is at $30.0 million. The company's, Q4 earnings came out yesterday. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares decreased by 29.88% to $2.88. The market value of their outstanding shares is at $43.7 million. </li>
<li>CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) stock decreased by 24.23% to $0.23. The company's market cap stands at $9.8 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 18.67% to $92.9. The company's market cap stands at $9.8 billion. </li>
<li>Citius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTXR#NASDAQ">CTXR</a>) shares decreased by 18.13% to $1.22. The market value of their outstanding shares is at $10.4 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares declined by 17.7% to $5.07. The company's market cap stands at $80.4 million. As per the news, the Q4 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

CARM

CTXR

ELTX

HEPA

NUTX

RSLS

RVPH

TCRT

YCBD

12 Health Care Stocks Moving In Tuesday's Intraday Session

Investors with a lot of money to spend have taken a bearish stance on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CORT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Corcept Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 13% bullish and 73%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $599,257, and 4 are calls, for a total amount of $1,067,250.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $65.0 and $115.0 for Corcept Therapeutics, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Corcept Therapeutics's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Corcept Therapeutics's substantial trades, within a strike price spectrum from $65.0 to $115.0 over the preceding 30 days.
<h3>Corcept Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743522331_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$33.4</td>
<td>$31.4</td>
<td>$32.8</td>
<td>$65.00</td>
<td>$984.0K</td>
<td>1.7K</td>
<td align="right">310</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$9.0</td>
<td>$8.1</td>
<td>$8.8</td>
<td>$100.00</td>
<td>$88.0K</td>
<td>556</td>
<td align="right">520</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$29.4</td>
<td>$28.1</td>
<td>$29.76</td>
<td>$100.00</td>
<td>$74.1K</td>
<td>0</td>
<td align="right">53</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$29.0</td>
<td>$25.8</td>
<td>$28.5</td>
<td>$100.00</td>
<td>$70.6K</td>
<td>0</td>
<td align="right">0</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$7.4</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$100.00</td>
<td>$70.0K</td>
<td>556</td>
<td align="right">160</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
Following our analysis of the options activities associated with Corcept Therapeutics, we pivot to a closer look at the company's own performance.
<h3>Current Position of Corcept Therapeutics</h3>
<ul>
<li>With a trading volume of 3,215,057, the price of CORT is up by 0.53%, reaching $114.82.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 29 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Corcept Therapeutics</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $147.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $142. 
&#x2A; An analyst from HC Wainwright &amp; Co. persists with their Buy rating on Corcept Therapeutics, maintaining a target price of $150. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $150. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Corcept Therapeutics with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

Corcept Therapeutics Unusual Options Activity For April 01

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $130 to $142.

Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $142

7 analysts have expressed a variety of opinions on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $116.86, a high estimate of $150.00, and a low estimate of $78.00. This current average reflects an increase of 33.88% from the previous average price target of $87.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1743451250_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Corcept Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corcept Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Corcept Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>Get to Know Corcept Therapeutics Better</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
<h3>Key Indicators: Corcept Therapeutics's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Corcept Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 34.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.71%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.61%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Corcept Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 3.74%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Corcept Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings)

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">central review (PFS-BICR)</a>.
In ROSELLA, patients treated with relacorilant and nab-paclitaxel chemotherapy experienced a 30% reduction in the risk of disease progression compared to patients treated with nab-paclitaxel alone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42483672/corcept-therapeutics-fda-approved-korlym-hits-main-goal-in-cushings-syndrome-patients-with-difficult-to-control-diabetes" rel="noreferrer noopener">Corcept Therapeutics&#8217; FDA-Approved Korlym Hits Main Goal In Cushing&#8217;s Syndrome Patients With Difficult-To-Control Diabetes</a>
The median PFS-BICR was 6.5 months, compared to 5.5 months in patients who received <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44559343/primary-endpoint-met-in-corcepts-pivotal-phase-3-rosella-trial-of-relacorilant-in-patients-with-pl" rel="noreferrer noopener">nab-paclitaxel alone</a>.
At an interim evaluation of overall survival (OS), patients treated with relacorilant plus nab-paclitaxel had a significant improvement in OS, with a median OS of 16.0 months, compared to 11.5 months for patients receiving nab-paclitaxel alone.
Relacorilant was well-tolerated and no new safety signals were observed.
The complete results of ROSELLA will be presented at a medical conference this year.
The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer.
Analyst Reaction:
<ul>
<li>HC Wainwright maintains Corcept Therapeutics with a Buy, raising the price target <a href="https://www.benzinga.com/quote/CORT/analyst-ratings" target="_blank" rel="noreferrer noopener">from $115 to $150</a>.</li>
<li>Truist Securities maintains Corcept Therapeutics with a Buy, raising the price target from $76 to $150.</li>
</ul>
Price Action: CORT is up 85.6% at $101.80 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544148/hb-fuller-faces-growth-hurdles-jp-morgan-analyst-slashes-price-forecast-amid-declining-sales-in-health-hygiene-and-consumable-segment" target="_blank" rel="noreferrer noopener">JP Morgan Slashes H.B. Fuller Price Forecast For Softening Growth</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Health Care

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

<h3>Gainers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock moved upwards by 88.8% to $103.12 during Monday's regular session. The market value of their outstanding shares is at $10.8 billion. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 38.2% to $35.48. The company's market cap stands at $461.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares rose 34.34% to $0.89. The market value of their outstanding shares is at $63.9 million. </li>
<li>bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) shares rose 26.41% to $5.16. The market value of their outstanding shares is at $50.2 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) shares moved upwards by 13.95% to $0.57. The company's market cap stands at $8.3 million. </li>
<li>ABVC BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVC#NASDAQ">ABVC</a>) stock rose 13.34% to $0.97. The market value of their outstanding shares is at $23.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares declined by 46.9% to $36.92 during Monday's regular session. The company's market cap stands at $4.7 billion. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares fell 34.87% to $0.99. The market value of their outstanding shares is at $11.3 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock declined by 30.87% to $0.65. The company's market cap stands at $3.4 million. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares fell 30.06% to $1.35. The market value of their outstanding shares is at $276.7 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 27.49% to $0.35. The market value of their outstanding shares is at $1.5 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares decreased by 23.08% to $11.17. The market value of their outstanding shares is at $166.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABVC

BLUE

CTOR

NGNE

NIVF

PCVX

PLRZ

TSHA

12 Health Care Stocks Moving In Monday's Intraday Session

Truist Securities analyst Joon Lee maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $76 to $150.

Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

Financial giants have made a conspicuous bullish move on Corcept Therapeutics. Our analysis of options history for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) revealed 38 unusual trades.
Delving into the details, we found 42% of traders were bullish, while 34% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $282,776, and 34 were calls, valued at $3,592,834.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $110.0 for Corcept Therapeutics, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Corcept Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Corcept Therapeutics's significant trades, within a strike price range of $20.0 to $110.0, over the past month.
<h3>Corcept Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743439542_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.9</td>
<td>$20.2</td>
<td>$20.6</td>
<td>$95.00</td>
<td>$412.0K</td>
<td align="right">0</td>
<td align="right">201</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$34.3</td>
<td>$31.3</td>
<td>$32.7</td>
<td>$90.00</td>
<td>$317.1K</td>
<td align="right">726</td>
<td align="right">200</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$32.5</td>
<td>$31.5</td>
<td>$31.5</td>
<td>$90.00</td>
<td>$315.0K</td>
<td align="right">726</td>
<td align="right">300</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$31.7</td>
<td>$28.3</td>
<td>$28.3</td>
<td>$90.00</td>
<td>$283.0K</td>
<td align="right">726</td>
<td align="right">100</td>
</tr>
<tr>
<td>CORT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$24.3</td>
<td>$22.0</td>
<td>$22.32</td>
<td>$100.00</td>
<td>$220.6K</td>
<td align="right">91</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.
After a thorough review of the options trading surrounding Corcept Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Corcept Therapeutics</h3>
<ul>
<li>With a trading volume of 8,640,882, the price of CORT is up by 85.93%, reaching $101.57.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 30 days from now.</li>
</ul>
<h3>What The Experts Say On Corcept Therapeutics</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $150.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $150. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Corcept Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Corcept Therapeutics's Options Frenzy: What You Need to Know

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $115 to $150.

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $150

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Monday.
The Dow traded up 0.30% to 41,710.68 while the NASDAQ fell 1.29% to 17,099.00. The S&amp;P 500 also fell, dropping, 0.41% to 5,557.99.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Consumer staples shares jumped by 1.2% on Monday.
In trading on Monday, consumer discretionary shares fell by 1.5%.
Top Headline
The Dallas Fed&#8217;s general business activity index for Texas manufacturing fell 8 points to a reading of -16.3 in March, declining to its weakest level since July 2024.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) shares shot up 10% to $35.70 after FB Financial announced it will acquire the company in a $381 million merger deal.</li>
<li>Shares of Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>)got a boost, surging 83% to $100.08 after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.</li>
<li>Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) shares were also up, gaining 17% to $122.49 after the company announced it will be acquired by Rocket Companies in a $9.4 billion all-stock deal.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares dropped 25% to $1.44.</li>
<li>Shares of Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) were down 51% to $34.26 after the company provided updates on the pneumococcal conjugate vaccine.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) was down, falling 33% to $0.6299 after the company announced it has terminated its proposed reverse merger with European Wellness.</li>
</ul>
Commodities In commodity news, oil traded up 2.6% to $71.14 while gold traded up 1.2% at $3,152.30.
Silver traded down 0.4% to $34.67 on Monday, while copper fell 1.9% to $5.0340.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 1.45%, Germany's DAX 40 fell 1.29% and France's CAC 40 declined 1.51%. Spain's IBEX 35 Index fell 1.17%, while London's FTSE 100 fell 0.82%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 4.05%, China's Shanghai Composite Index declining 0.46% and Hong Kong's Hang Seng Index dipping 1.31%.
Economics
<ul>
<li>The Chicago PMI climbed to 47.6 in March from 45.5 in the previous month and topping market estimates of 45.2.</li>
<li>The Dallas Fed&#8217;s general business activity index for Texas manufacturing fell 8 points to a reading of -16.3 in March, declining to its weakest level since July 2024.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo: Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

SSBK

Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet

U.S. stocks were mixed, with the Nasdaq Composite falling over 1% on Monday.
Shares of Mr. Cooper Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) rose sharply during Monday's session after the company announced it will be acquired by Rocket Companies in a $9.4 billion <a href="https://www.benzinga.com/quote/COOP">all-stock deal</a>.
Mr. Cooper Group shares jumped 16.3% to $ 121.54 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares jumped 84.7% to $100.95 after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.</li>
<li>United Microelectronics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UMC#NYSE">UMC</a>) shares rose 12.6% to $7.38.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) gained 12.6% to $28.20.</li>
<li>Southern States Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSBK#NASDAQ">SSBK</a>) rose 10.2% to $35.79 after FB Financial announced it will acquire the company in a $381 million merger deal.</li>
<li>B&amp;G Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGS#NYSE">BGS</a>) jumped 9.6% to $7.05.</li>
<li>Park Ha Biological Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHH#NASDAQ">PHH</a>) gained 9.5% to $14.00.</li>
<li>Cryoport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) gained 8.8% to $6.63 after DHL Group announced it will acquire its CRYOPDP business for $138 million.</li>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) rose 8.2% to $36.42.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) gained 7.6% to $8.20.</li>
<li>Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) rose 6.8% to $1.9550.</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) shares gained 5.4% to $167.34. Discover Financial Services will report its first quarter 2025 results after the market closes on Wednesday, April 23.</li>
<li>The Goodyear Tire &amp; Rubber Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GT#NASDAQ">GT</a>) gained 4% to $9.14. Deutsche Bank analyst Edison Yu upgraded Goodyear Tire &amp; Rubber from Hold to Buy and announced a $13 price target.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44554966/pvh-progress-software-and-3-stocks-to-watch-heading-into-monday">PVH, Progress Software And 3 Stocks To Watch Heading Into Monday</a></li>
</ul>
Photo: Shutterstock

CYRX

GRRR

NEXN

NVTS

Mr. Cooper Group, Southern States Bancshares, Corcept Therapeutics And Other Big Stocks Moving Higher On Monday

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 300 points on Monday.
Following the market opening Monday, the Dow traded down 0.27% to 41,473.52 while the NASDAQ fell 1.87% to 16,998.79. The S&amp;P 500 also fell, dropping, 0.91% to 5,530.01.
Check This Out: <a href="https://www.benzinga.com/25/03/44513063/jim-cramer-stryker-is-a-good-company-likes-this-utilities-stock">Jim Cramer: Stryker Is A &#8216;Good&#8217; Company, Says He Likes This Utilities Stock</a>
Leading and Lagging Sectors Energy shares jumped by 1.1% on Monday.
In trading on Monday, consumer discretionary shares fell by 2.1%.
Top Headline
The Chicago PMI climbed to 47.6 in March from 45.5 in the previous month and topping market estimates of 45.2.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>iCoreConnect Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCT#NASDAQ">ICCT</a>) shares shot up 148% to $0.6972.</li>
<li>Shares of Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>)got a boost, surging 83% to $100.17 after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.</li>
<li>Newton Golf Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTG#NASDAQ">NWTG</a>) shares were also up, gaining 55% to $2.3401.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares dropped 52% to $0.0163.</li>
<li>Shares of Vaxcyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) were down 53% to $32.55 after the company provided updates on the pneumococcal conjugate vaccine.</li>
<li>NewGenIvf Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) was down, falling 37% to $0.5950 after the company announced it has terminated its proposed reverse merger with European Wellness.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $70.41 while gold traded up 1% at $3,146.50.
Silver traded down 0.7% to $34.58 on Monday, while copper fell 2% to $5.0275.
Euro zone
European shares were lower today. The eurozone's STOXX 600 declined 1.5%, Germany's DAX 40 fell 1.5% and France's CAC 40 declined 1.5%. Spain's IBEX 35 Index fell 1.5%, while London's FTSE 100 fell 1%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 falling 4.05%, China's Shanghai Composite Index declining 0.46% and Hong Kong's Hang Seng Index dipping 1.31%.
Economics
The Chicago PMI climbed to 47.6 in March from 45.5 in the previous month and topping market estimates of 45.2.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44561974/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo: Shutterstock

ICCT

NWTG

Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March

Stifel Maintains Hold on Alphabet, Price Target From $184 To $167 &nbsp;

WIIM

Corcept Therapeutics shares are trading higher after the company announced it met its primary endpoint for its Phase 3 ROSELLA trial of Relacorilant.

Corcept Therapeutics Met Primary Endpoint In Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

<h3>Gainers</h3>
<ul>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 66.9% to $1.11 during Monday's pre-market session. The market value of their outstanding shares is at $79.4 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares rose 44.99% to $79.21. The market value of their outstanding shares is at $8.3 billion. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares moved upwards by 18.6% to $0.35. The market value of their outstanding shares is at $14.4 million. </li>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) shares rose 17.73% to $8.96. The market value of their outstanding shares is at $9.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) shares moved upwards by 15.78% to $0.85. The market value of their outstanding shares is at $2.3 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock rose 15.31% to $2.41. The market value of their outstanding shares is at $13.0 million. The company's, Q4 earnings came out 4 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vaxcyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) shares declined by 32.1% to $47.16 during Monday's pre-market session. The market value of their outstanding shares is at $6.0 billion. </li>
<li>PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) shares decreased by 19.8% to $0.6. The market value of their outstanding shares is at $8.2 million. As per the press release, Q4 earnings came out 4 days ago. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock declined by 19.69% to $0.02. </li>
<li>InnovAge Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INNV#NASDAQ">INNV</a>) shares fell 19.67% to $2.41. The market value of their outstanding shares is at $325.9 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock declined by 18.92% to $0.03. </li>
<li>SANUWAVE Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#NASDAQ">SNWV</a>) stock decreased by 17.93% to $30.0. The market value of their outstanding shares is at $256.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLM

APRE

INNV

LGMK

PAVM

SNWV

SPRB

STSS

12 Health Care Stocks Moving In Monday's Pre-Market Session

Investors with a lot of money to spend have taken a bullish stance on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with CORT, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 10 options trades for Corcept Therapeutics.
This isn't normal.
The overall sentiment of these big-money traders is split between 80% bullish and 10%, bearish.
Out of all of the options we uncovered, 9 are puts, for a total amount of $812,152, and there was 1 call, for a total amount of $33,000.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $35.0 to $65.0 for Corcept Therapeutics over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Corcept Therapeutics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Corcept Therapeutics's whale trades within a strike price range from $35.0 to $65.0 in the last 30 days. 
<h3>Corcept Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740685582_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.4</td>
<td>$6.6</td>
<td>$6.9</td>
<td>$65.00</td>
<td>$138.0K</td>
<td>1.1K</td>
<td align="right">500</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.9</td>
<td>$8.3</td>
<td>$8.4</td>
<td>$65.00</td>
<td>$126.0K</td>
<td>1.1K</td>
<td align="right">800</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.2</td>
<td>$5.6</td>
<td>$6.15</td>
<td>$65.00</td>
<td>$123.0K</td>
<td>1.1K</td>
<td align="right">250</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.6</td>
<td>$7.5</td>
<td>$7.85</td>
<td>$65.00</td>
<td>$117.7K</td>
<td>1.1K</td>
<td align="right">650</td>
</tr>
<tr>
<td>CORT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.8</td>
<td>$6.0</td>
<td>$6.0</td>
<td>$60.00</td>
<td>$101.0K</td>
<td>2.4K</td>
<td align="right">372</td>
</tr>
</tbody>
</table>

<h3>About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
In light of the recent options history for Corcept Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Corcept Therapeutics's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,264,941, the CORT's price is down by -6.14%, now at $59.48. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 62 days.</li>
</ul>
<h3>Professional Analyst Ratings for Corcept Therapeutics</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $103.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $115. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Corcept Therapeutics, targeting a price of $130. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Corcept Therapeutics, which currently sits at a price target of $78. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $80. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Buy, adjusting the price target to $115. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Corcept Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Corcept Therapeutics's Options: A Look at What the Big Money is Thinking

Press Releases

Kuehn Law Encourages Investors of Corcept Therapeutics Inc. to Contact Law Firm

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Corcept Therapeutics

Notizie

Ultime notizie per Corcept Therapeutics (NASDAQ:CORT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO